Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship.
about
Scorpion toxins specific for potassium (K+) channels: a historical overview of peptide bioengineeringMarine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immunDeterminants of alpha-conotoxin BuIA selectivity on the nicotinic acetylcholine receptor beta subunitBioactive marine drugs and marine biomaterials for brain diseasesCone snail venomics: from novel biology to novel therapeutics.Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram.A novel conotoxin, qc16a, with a unique cysteine framework and foldingMarine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.Therapeutic potential of conopeptides.Therapeutic conotoxins: a US patent literature survey.The role of defensive ecological interactions in the evolution of conotoxins.Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties.Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter.Molecular Engineering of Conus Peptides as Therapeutic Leads.Conotoxins: Therapeutic Potential and Application.Inhibition of the norepinephrine transporter by χ-conotoxin dendrimersχ-Conotoxin and Tricyclic Antidepressant Interactions at the Norepinephrine Transporter Define a New Transporter Model
P2860
Q26853728-5CBF6521-D803-49B0-918F-A577EB84EC5AQ33280358-1F88CB8D-F670-4789-AC7B-24E2B59F338CQ33668630-2EAB7377-CEC9-470C-B066-638C61AF0555Q33736687-63592A78-DF57-4F54-8C75-5A27FA360D75Q35432836-4876AFBA-76B1-42A7-ADE4-B11D32DBE7E1Q36439975-84F85076-61F6-4F14-B91B-1AC64D4C529CQ36541551-65145350-0C9D-44D8-856D-40316F8EF175Q37566220-0CB32E54-0D40-4F93-BB50-781370388FFFQ38026605-39F0C88E-BA99-4646-BDE2-41CE7D4AAFFAQ38525254-9E669D21-B153-4CF8-8E9C-6CF530D689A0Q38816124-DBB5F19D-16B2-4402-B5FB-3E5765E46DF5Q39093085-D251536A-0567-4826-B913-16802A086988Q39293366-24C3A170-DA9B-49B7-8FAD-303AA61DC42DQ44499448-8A5B2519-2231-472B-B5A9-A98F500CB77CQ46272595-0330C493-E68D-4A3F-8E9C-692669A8FE1BQ46364124-5B1B35E9-D610-45B9-9C42-BD0D8282DBA2Q58284339-D93704A7-BD89-4E51-A02F-B551A654D90DQ58427018-9499AEA6-14D5-4804-A6C4-053DFDD41E3A
P2860
Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Inhibition of the norepinephri ...... ructure-activity relationship.
@en
Inhibition of the norepinephri ...... ructure-activity relationship.
@nl
type
label
Inhibition of the norepinephri ...... ructure-activity relationship.
@en
Inhibition of the norepinephri ...... ructure-activity relationship.
@nl
prefLabel
Inhibition of the norepinephri ...... ructure-activity relationship.
@en
Inhibition of the norepinephri ...... ructure-activity relationship.
@nl
P2093
P2860
P50
P356
P1476
Inhibition of the norepinephri ...... ructure-activity relationship.
@en
P2093
David M Kaye
Elka Palant
Iain A Sharpe
Paul F Alewood
P2860
P304
40317-40323
P356
10.1074/JBC.M213030200
P407
P577
2003-07-28T00:00:00Z